OverviewSuggest Edit

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system diseases, pain and various types of cancer. The Company’s lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
TypePublic
Founded2006
HQNew York, US
Websiteanavex.com

Latest Updates

Employees (est.) (Feb 2019)13(+30%)
Share Price (Jun 2019)$3 (+3%)

Key People/Management at Anavex

Christopher U. Missling

Christopher U. Missling

CEO
Tom Skarpelos

Tom Skarpelos

Director
Tasos Zografidis

Tasos Zografidis

Vice President Clinical Operations
Ulrich Elben

Ulrich Elben

Vice President of Preclinical Operations
Show more

Anavex Office Locations

Anavex has offices in New York and Reno
New York, US (HQ)
51 W 52nd St
Reno, US
50 W. Liberty, 50 W Liberty St #880
Show all (2)

Anavex Financials and Metrics

Anavex Revenue

USD

Market capitalization (10-Jun-2019)

149.3m

Closing stock price (10-Jun-2019)

3.0

Cash (30-Sep-2018)

22.9m
Anavex's current market capitalization is $149.3 m.
USDFY, 2016FY, 2017

General and administrative expense

8.3m5.0m

R&D expense

7.3m10.7m

Operating expense total

(15.6m)(15.7m)

Depreciation and amortization

Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

345.1k15.3m9.2m27.4m22.9m

Current Assets

393.4k

Total Assets

393.4k9.5m27.8m24.4m

Accounts Payable

1.7m2.5m52.4k52.4k52.4k
Quarterly
USDQ1, 2014Q2, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018Q3, 2018

Cash

95.9k9.2m13.9m12.0m9.7m21.2m24.8m25.7m25.8m

Current Assets

148.8k9.2m

Total Assets

150.9k10.3m14.0m12.1m9.8m21.4m24.9m25.9m26.8m

Accounts Payable

1.6m1.7m2.4m2.3m2.1m52.4k52.4k52.4k52.4k
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(3.7m)(12.1m)(14.7m)(13.5m)(17.5m)

Depreciation and Amortization

576.0995.01.3k

Accounts Payable

465.9k1.3m775.3k554.7k300.3k

Cash From Operating Activities

(777.6k)(4.2m)(9.2m)(9.0m)(12.6m)
Quarterly
USDQ1, 2014Q2, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q2, 2018Q3, 2018

Net Income

(660.2k)(4.0m)(6.0m)(8.2m)(3.1m)(8.3m)(8.8m)(11.7m)

Depreciation and Amortization

192.0384.0249.0497.0746.0

Accounts Payable

(79.9k)(22.5k)(86.3k)(14.2k)(294.8k)(956.5k)(1.6m)(167.6k)(375.3k)

Cash From Operating Activities

(435.0k)(782.5k)(3.2m)(5.1m)(7.4m)(3.2m)(6.8m)(6.4m)(8.5m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Anavex Online and Social Media Presence

Embed Graph

Anavex News and Updates

Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association International Conference (AAIC)

NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease,…

Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference

NEW YORK, April 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease…

Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update

Conference Call and Webcast Today at 4:30 p.m. ET Conference Call and Webcast Today at 4:30 p.m. ET

First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)

Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers

Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

Late-Breaking Data Demonstrate Significant Association Between Higher ANAVEX®2-73 Concentration and Maintained Activities of Daily Living and Reduced Cognitive Decline in Alzheimer’s Disease Patients
Show more

Anavex Blogs

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome Both global efficacy endpoints, RSBQ and CGI-I, showed significant improvement with respect to baseline after 7 weeks of treatment with ANAVEX®2-73 (blar…

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019   NEW YORK – September 5, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative an…

Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome

Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome NEW YORK – September 4, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing different…

Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results and Provides Clinical Study Updates

 Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results  And Provides Clinical Study Updates Conference Call and Webcast Today at 4:30 p.m. ET   NEW YORK – August 7, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical com…

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019 Conference Call and Webcast To be Held Wednesday August 7, 2019 4:30pm Eastern Time NEW YORK – August 2, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical…

Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome   NEW YORK – July 31, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage bioph…
Show more

Anavex Frequently Asked Questions

  • When was Anavex founded?

    Anavex was founded in 2006.

  • Who are Anavex key executives?

    Anavex's key executives are Christopher U. Missling, Tom Skarpelos and Tasos Zografidis.

  • How many employees does Anavex have?

    Anavex has 13 employees.

  • Who are Anavex competitors?

    Competitors of Anavex include Citryll, Shanghai Henlius Biotech and Celgene.

  • Where is Anavex headquarters?

    Anavex headquarters is located at 51 W 52nd St, New York.

  • Where are Anavex offices?

    Anavex has offices in New York and Reno.

  • How many offices does Anavex have?

    Anavex has 2 offices.